ORIGIO a/s, a listed medtech company on the Oslo 
Stock Exchange (OSE: ORO) has issued its fourth 
quarter report for 2011. The Q4 report is available 
on ORIGIO's website (www.origio.com) and through the 
Oslo Børs Information System. 

Financial highlights, Q4, 2011
·Revenue in Q4 2011 of DKK 96.2 million which is 19% 
higher than Q4 2010. Revenue for 2011 totaled DKK 
370.1 million, equal to an increase of 20% 
·Organic growth in constant currencies of 16% in Q4, 
2011 and 20% for full year 2011
·EBITDA before special items increased by 44% in Q4, 
2011 to DKK 13.4 million (14.0% of revenue) and by 
32% to DKK 57.8 million (15.6% of revenue) for full 
year 2011
·Operating cash flow of DKK 11.3 million in Q4, 2011 
vs. DKK 17.9 million in Q4, 2010. Operating cash flow 
in 2011 amounted to DKK 23.5 million, which is DKK 
5.1 million lower than 2010 
·Special items of DKK -12.8 million for the quarter 
and DKK -16.2 million for 2011. Of this, DKK 12 
million relates to write-down of ORIGIO's former 
headquarter in Jyllinge 

Selected Strategic and Operational Highlights
·Acquisition of the Dutch manufacturer of ART oocyte 
retrieval needles and embryo transfer catheters, 
Artworks B.V., completed in October, 2011
·EmbryoGen®; live birth data from clinical study 
supported significant improved effect in patients 
with previous miscarriage. The novel ART culture 
medium is successfully launched in more than 40 
countries
·EmbryoSure®; new improved agreement involving 
increasing partners' contribution to risk sharing 
(January 26, 2012)
·New R&D project regarding the GM-CSF technology for 
culturing embryos until day 5 (blastocyst) initiated 


Financial outlook 2012 
·Revenue for 2012 is estimated to be minimum DKK 425 
million. This entails a constant currency organic 
growth rate of minimum 10%
·EBITDA% before special items is expected to be in 
the range of 15-17%
·The financial outlook is based on a USD exchange 
rate of DKK 5.50